Wuhan Weike Medical's DOCS VALVE: A Globally First-in-Class, Dual-Indication TAVR System Poised to Halve Costs Upon 2027 Launch

Recently, the finals of the 2024 Global Alumni Innovation and Entrepreneurship Competition in the Medical-Engineering Integration and Healthcare Track were held at Huazhong University of Science and Technology.Wuhan Vickor Medical Technology Co., Ltd.(Abbreviation: Vickor Medical)Self-developedTranscatheter Aortic Valve Replacement System (DOCS VALVE)Awarded the Special Prize for Growth Group。Recently,This MedTech company has completed the signing of the Series C financing agreement, with a valuation of 2 billion yuan.。

Vickor's R&D Director, Sun Ming, stated: "Currently, the price of foreign heart valve products is over 200,000 yuan. We hope...After this product achieves domestic substitution,Can reduce costs by at least half", allowing ordinary people in China to truly afford this high-end medical device product."

Valvular disease in China is commonly characterized by aortic regurgitation, with approximately 4 million patients affected.Currently approved and marketed percutaneous path localized valve products are all used for stenotic lesions,Lack of Valve Products for Reflux LesionsIn addition, mainstream traditional valve replacement surgery requires general anesthesia and cardiopulmonary bypass, which is highly invasive and has a surgical mortality rate as high as 20%.

Vickor has independently developed a transcatheter aortic valve replacement system.No general anesthesia and pacemaker required, minimally invasive surgery only takes 40 minutes. Its self-developed percutaneous pathway valve productCan simultaneously meet the dual indication requirements of stenosis and regurgitation.，A global first。

It is reported that,The product is scheduled to be launched in 2027, capable of meeting at least 10,000 surgeries annually.。Currently, Vickor has established a complete production line for the entire series of valves, used for batch production and manufacturing of products.